Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02175121 · ClinicalTrials.gov registry record · Phase 2

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

A Phase 2 study of Diabetes Mellitus Type II, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
172
Enrollment target
19
Study locations

NCT02175121 is a Phase 2 study of Diabetes Mellitus Type II that has completed, run by Pfizer. The registered enrollment target is 172 participants, below the 216-participant average among 7 other Diabetes Mellitus Type II trials with a reported enrollment target (20% lower). The trial reports 19 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02175121, a Phase 2 study of Diabetes Mellitus Type II, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
172 participants
Enrollment target
19
Study locations

Study Summary

This study is going to assess the safety and tolerability of PF-06291874 in adults with Type 2 Diabetes Mellitus as monotherapy, to evaluate the significance of overall glycemic control in these subjects.

Conditions Studied

Diabetes Mellitus Type II

Interventions

  • DRUG Placebo
  • DRUG PF-06291874

Study Locations (19)

Florida

  • Avail Clinical Research, LLC - DeLand
  • SeaView Research, Inc. - Miami
  • SeaView Research, Inc. - Miami
  • Compass Research, LLC - Orlando
  • Miami Research Associates, Inc. - South Miami
  • MRA Clinical Research, LLC - South Miami
  • MRA Clinical Research - South Miami

California

  • Anaheim Clinical Trials, LLC - Anaheim
  • Profil Institute for Clinical Research, Inc. - Chula Vista
  • Diablo Clinical Research, Inc. - Walnut Creek

New Jersey

  • Clinilabs, Inc. - Eatontown
  • PRA International - Marlton

Kentucky

  • Louisville Metabolic and Atherosclerosis Research Center - Louisville

Minnesota

  • DaVita Clinical Research - Minneapolis

New York

  • Buffalo Clinical Research Center, LLC - Buffalo

North Carolina

  • High Point Clinical Trials Center, LLC - High Point

Ohio

  • Community Research - Cincinnati

Trial Details

FieldValue
Enrollment Target 172 participants
Start Date 2014-08
Est. Completion 2015-03
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02175121

The ClinicalTrials.gov registry entry for NCT02175121 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 216-participant average among 7 other Diabetes Mellitus Type II trials with a reported enrollment target (20% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus Type II appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02175121 reports 19 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, New Jersey.

Frequently Asked Questions

What is clinical trial NCT02175121 about?

NCT02175121 is a clinical study titled "Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus". This study is going to assess the safety and tolerability of PF-06291874 in adults with Type 2 Diabetes Mellitus as monotherapy, to evaluate the significance of overall glycemic control in these subjects.

What is the current status of trial NCT02175121?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2014-08. Estimated completion is 2015-03.

What conditions does trial NCT02175121 study?

This clinical trial studies the following conditions: Diabetes Mellitus Type II.

What interventions are being tested in trial NCT02175121?

The interventions under investigation include: Placebo (DRUG), PF-06291874 (DRUG).

Who is sponsoring clinical trial NCT02175121?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02175121 being conducted?

This trial has 19 study locations across California, Florida, Kentucky, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus Type II

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus Type II

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.